CareDx (CDNA) counsel’s RSU vesting triggers 1,892-share tax withholding
CareDx, Inc.'s Secretary and General Counsel, Jeffrey Adam Novack, had 1,892 shares of common stock withheld to cover tax obligations upon the vesting of restricted stock units. This transaction, valued at $17.82 per share, was a routine tax-withholding disposition and not an open-market sale. Following this, Novack directly holds 119,485 shares of CareDx common stock, maintaining a significant equity stake.
Price-Driven Insight from (CDNA) for Rule-Based Strategy
This article provides a price-driven insight for Caredx Inc. (NASDAQ: CDNA), highlighting strong near-term sentiment that could lead to a long-term positive bias. It presents exceptional risk-reward setups with specific entry, target, and stop-loss zones for various trading strategies derived from AI models, along with multi-timeframe signal analysis.
CareDx (NASDAQ: CDNA) CCO covers RSU taxes with 7,386 shares
CareDx, Inc.'s Chief Commercial Officer, Jessica Meng, had 7,386 shares of Common Stock withheld to cover tax withholding obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $17.87 per share, was a non-market event for tax purposes and not an open-market sale or purchase. Following this, Meng directly holds 169,392 shares of CareDx common stock.
CareDx (CDNA) GC has 3,987 shares withheld for RSU taxes
CareDx, Inc.'s Secretary and General Counsel, Jeffrey Adam Novack, had 3,987 shares of common stock withheld on April 1, 2026. This action was taken to cover tax obligations arising from the vesting of restricted stock units, and the shares were retained by the company at a price of $17.87 per share. Following this transaction, Novack directly holds 121,377 shares of CareDx common stock.
CareDx (CDNA) director receives automatic quarterly stock grant
CareDx, Inc. director Michael Goldberg received an automatic quarterly grant of 1,981 shares of common stock on April 2, 2026. This grant, valued at $0.00 per share, was provided in lieu of cash compensation under the company’s Outside Director Compensation Policy. Following this transaction, Goldberg directly holds 185,942 common shares in CareDx.
CareDx (CDNA) director exercises 26,500 options, now holds 183,961 shares
CareDx (CDNA) director Michael Goldberg exercised stock options for 26,500 shares on March 31, 2026, at exercise prices of $5.02, $4.95, and $1.22 per share. Following these transactions, Goldberg directly owns 183,961 shares of CareDx common stock. The exercised options had vesting schedules that began in 2016 and 2017, and no sales were reported in this Form 4 filing.
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of "Hold" from Analysts
CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" recommendation from nine analysts, with an average 12-month price target of $27.33. The company missed EPS estimates in its latest quarterly results but saw a 25.2% year-over-year revenue increase, with analysts forecasting a negative EPS for the current year. Insider selling has also been noted, with CEO John W. Hanna Jr. selling shares totaling over $400,000.
[SCHEDULE 13G/A] CareDx, Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an Amended Schedule 13G/A for CareDx, Inc., reporting 0 shares beneficially owned as of March 13, 2026, representing 0% of Common Stock. This change follows an internal realignment at Vanguard on January 12, 2026, where certain subsidiaries will now report holdings separately based on SEC Release No. 34-39538. The filing indicates a compliance-driven amendment, with future ownership details expected from individual Vanguard subsidiaries.
CareDx (NASDAQ:CDNA) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?
CareDx (NASDAQ:CDNA) shares recently fell below their 200-day moving average, a potentially bearish technical signal, despite a revenue beat in their latest earnings report. The company missed EPS estimates, and insiders have been selling shares, although institutional investors like Goldman Sachs have increased their positions. Analysts currently hold a consensus "Hold" rating for the stock.
(CDNA) Price Dynamics and Execution-Aware Positioning
This article analyzes Caredx Inc. (NASDAQ: CDNA) stock dynamics, identifying a neutral near-term sentiment that could moderate mid-term weakness. It highlights an exceptional risk-reward short setup and provides detailed institutional trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss zones. The analysis is supported by AI-generated multi-timeframe signals outlining support and resistance levels.
CareDx, Inc. (CDNA) Stock Price Today | Live Chart & News
This article provides current stock price information, live charts, and news for CareDx, Inc. (CDNA). It includes detailed stock statistics, performance metrics, financial fundamentals, and short-term and long-term price predictions. The piece also features a compilation of recent market news, including articles related to other companies like Apple, Starbucks, and Tilray.
CareDx (CDNA) Launches AI-based Platform VANTx
CareDx, Inc. (NASDAQ: CDNA) has launched VANTx, an AI-powered, cloud-native platform designed to convert complex transplant data into actionable clinical insights using Llama 3 and advanced machine learning. Introduced at the 2026 Precision Medicine World Conference, the platform is initially available via medical consultation with plans for broader clinician access later in 2026. This launch follows BTIG raising its price target on CareDx from $25 to $26, maintaining a Buy rating after positive Q4 results.
If You Invested $1,000 in Caredx (CDNA)
This article analyzes the historical performance of an investment in CareDx (CDNA), a precision medicine company focused on transplant medicine. It details how a $1,000 investment would have fared over one, five, and ten years, including annual returns and comparison to the S&P 500. The piece also provides an overview of CareDx's business, its products and services for transplant patients, and its financial and corporate governance information.
Fred Alger Management LLC Sells 304,736 Shares of CareDx, Inc. $CDNA
Fred Alger Management LLC has reduced its stake in CareDx, Inc. by 24.7%, selling 304,736 shares and now holding 929,023 shares valued at approximately $13.51 million. This comes as CareDx reported mixed quarterly results, beating revenue estimates but missing on EPS, and faces a consensus "Hold" rating from analysts. Insider selling has also occurred, with the CEO divesting a significant portion of shares.
Portolan Capital Management LLC Grows Stake in CareDx, Inc. $CDNA
Portolan Capital Management LLC significantly increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 48.2% in the third quarter of 2025, now owning 933,532 shares valued at approximately $13.6 million. Despite the institutional buying, CEO John Walter Hanna Jr. sold shares, reducing his holdings, and other insiders have also sold shares recently. CareDx's last quarterly earnings missed EPS estimates but exceeded revenue forecasts, with analysts holding a consensus "Hold" rating on the stock.
Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA
Bamco Inc. NY significantly increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 29.5% in the third quarter, now owning 6.13% of the company worth $45.88 million. Other institutional investors also adjusted their holdings, while CEO John Walter Hanna, Jr. sold a portion of his shares. CareDx's stock recently traded at $17.01, with analysts issuing mixed ratings and a consensus price target of $27.33.
CareDx introduces VANTx AI platform for complex transplant datasets
CareDx has launched VANTx, an AI platform designed to analyze complex transplant patient data, including genomics, allowing for a more comprehensive understanding of individual transplant recipients. This platform aims to provide care teams with deeper insights to improve patient outcomes. VANTx is presented as a next-generation solution for transplant patient management.
Braidwell LP Makes New Investment in CareDx, Inc. $CDNA
Braidwell LP has made a significant new investment in CareDx, Inc. (NASDAQ:CDNA), purchasing over 2.18 million shares valued at approximately $31.74 million, which represents about 4.24% of the company. This investment comes as CareDx posted a revenue beat but an EPS miss in its latest quarter, alongside a negative net margin. Analyst ratings for CareDx are currently mixed, with an average "Hold" rating and a price target of $27.33, despite some recent upgrades and downgrades by various firms.
Prosight Management LP Grows Stock Holdings in CareDx, Inc. $CDNA
Prosight Management LP significantly increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 66.5% during the third quarter, bringing its total holdings to 504,030 shares valued at $7.33 million. The firm now holds approximately 0.98% of CareDx, making it their 23rd largest position. This increase comes amid mixed analyst ratings for CareDx and recent insider selling by the company's CEO, John W. Hanna Jr.
(CDNA) as a Liquidity Pulse for Institutional Tactics
The article analyzes Caredx Inc. (NASDAQ: CDNA) using AI models, revealing a weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and highlights an exceptional short setup with a high risk-reward ratio. Three distinct institutional trading strategies are provided, tailored to different risk profiles and holding periods, alongside multi-timeframe signal analysis.
CareDx raises 2025 revenue guidance to $372M–$376M with robust RCM gains and new product launches
CareDx has raised its 2025 revenue guidance to a range of $372 million to $376 million, an increase from its previous forecast of $357 million to $365 million. This upward revision is attributed to strong growth in its Transplant Services net new patient testing, robust RCM (Revenue Cycle Management) gains, and the anticipated launch of new products. The company's updated outlook reflects confidence in its market performance and strategic initiatives.
CareDx Launches VANTx AI Solution for Advanced Transplant Data Analysis
CareDx has launched VANTx, a new cloud-based AI platform designed for advanced transplant data analysis, which was unveiled at the Precision Medicine World Conference. The platform uses AI to generate insights from complex transplant data for clinical research and evidence generation. Despite an initial 8.5% stock decline, CareDx's shares have risen 26.8% over the past six months, outperforming industry averages.
CareDx Launches VANTx AI Solution for Advanced Transplant Data Analysis
CareDx (CDNA) has introduced VANTx, a new cloud-based platform utilizing AI to analyze complex transplant data for clinical research and real-world evidence. The platform, presented by CareDx's Chief Data and AI Officer, Jing Huang, aims to transform transplant care through AI-driven insights. While CDNA shares initially declined, the launch signifies a strategic expansion for CareDx beyond diagnostics, leveraging proprietary datasets and advanced AI for comprehensive, data-driven transplant solutions.
CareDx Introduces VANTx AI Platform for Complex Transplant Datasets
CareDx has launched VANTx, an AI-driven, cloud-based platform designed to convert complex transplant datasets into actionable insights for clinical research and real-world evidence. The platform, introduced at the Precision Medicine World Conference, aims to strengthen CareDx's position in integrated data-driven transplant care by leveraging proprietary datasets and advanced AI. VANTx supports cohort analysis, treatment pattern evaluation, and integrates various data sources, with plans for expanded self-service access later in 2026.
CareDx, Inc. (NASDAQ:CDNA) Given Consensus Rating of "Hold" by Analysts
CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine analyst firms with an average one-year target price of $27.33. Recent analyst reports show a mix of ratings, including upgrades and downgrades, with some firms raising price targets while others lowered their ratings. Insider activity indicates CEO John Walter Hanna, Jr. sold a significant number of shares, while institutional investors have been modifying their holdings in the company.
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
CareDx has announced VANTx™, a new AI-powered clinical data and analytics platform designed for solid organ transplant patients. The platform leverages CareDx's extensive proprietary datasets to provide insights for improving patient care and outcomes. VANTx™ aims to enhance transplant medicine through advanced data analytics and artificial intelligence.
CareDx launches AI platform for transplant research By Investing.com
CareDx Inc. (NASDAQ:CDNA) has announced the launch of VANTx, a new cloud-based artificial intelligence platform designed for transplant program data analysis and clinical research. The platform leverages de-identified molecular test data and predictive models to improve treatment protocols and clinical trial design for various organ transplants. CareDx, which has seen its stock rise significantly, maintains a strong financial position and is expected to become profitable this year, according to InvestingPro analysis.
CareDx launches AI platform for transplant research
CareDx Inc. (NASDAQ: CDNA) has launched VANTx, a cloud-based AI platform designed for transplant program data analysis and clinical research. The platform, introduced at the Precision Medicine World Conference, uses de-identified molecular tests and clinical trial data to evaluate treatment trends and outcomes, supporting clinicians and pharmaceutical partners in developing treatment protocols. CareDx, which has seen its stock surge nearly 38% in the past six months, is also financially robust with strong revenue and gross profit margins, with analysts predicting profitability this year.
CareDx (CDNA) Introduces VANTx: A Revolutionary AI Data Platform for Transplants
CareDx (CDNA) has launched VANTx, an AI-driven platform designed to transform transplant data into actionable insights for clinical research and evidence generation. This cloud-based solution aims to help healthcare professionals, transplant centers, and pharmaceutical partners analyze patient cohorts, assess treatment trends, and guide clinical trials. While CareDx demonstrates strong financial health with robust liquidity and low leverage, it faces challenges with declining operating margins and notable insider selling activity.
Royce & Associates LP Has $5.88 Million Stake in CareDx, Inc. $CDNA
Royce & Associates LP significantly reduced its stake in CareDx, Inc. by 48.1% in Q3, now holding shares valued at $5.88 million. Despite this, other institutions like Next Century Growth Investors and Sumitomo Mitsui Trust Group increased their positions, and SG Capital initiated a new stake. Analysts are mixed on CareDx, with a consensus "Hold" rating and an average price target of $27.33, following a recent earnings per share miss but a 25.2% year-over-year revenue increase.
First Eagle Investment Management LLC Buys 96,123 Shares of CareDx, Inc. $CDNA
First Eagle Investment Management LLC increased its stake in CareDx, Inc. by 25.4% in the third quarter, purchasing an additional 96,123 shares. This makes their total holdings 475,146 shares, valued at $6.91 million. Other hedge funds also adjusted their positions in CDNA, while analyst ratings on the stock are mixed, with a consensus of "Hold" and an average target price of $27.33.
Caredex Stock Quote, Share Price, News and Analysis
This article provides financial news and analysis for Caredex (CDNA.US), including recent earnings releases and related events. It details the company's FY2025 Q4 and Annual earnings, highlighting revenue and EPS figures against forecasts, along with information on new product launches and study results. The page also includes schedules for earnings releases and a list of top-performing stocks.
CDNA,SPOK Options
This article provides detailed financial data, analyst ratings, and insider transaction information for two companies: Caredx Inc (CDNA) and Spok Holdings Inc (SPOK). It includes current stock prices, market capitalization, P/E ratios, sales figures, and recent news headlines for both companies, along with a comprehensive list of insider stock sales and option exercises. The data highlights recent financial results, analyst upgrades/downgrades, and significant corporate announcements for each company.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. announced the award of inducement grants to 35 new employees on February 24, 2026. These grants consist of restricted stock units (RSUs) for a total of 82,137 shares of common stock, made under the company's 2016 and 2025 Inducement Equity Incentive Plans. The RSUs will vest over four years, with specific vesting schedules contingent on continuous employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
CDNA SEC Filings - Caredx 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for CareDx (CDNA) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries of key documents. It highlights recent insider trading activities, such as director Michael Goldberg's stock grant, Hannah Valantine's planned stock sale under a 10b5-1 plan, and Peter Maag's stake reduction, also under a 10b5-1 plan, along with a Form 144 filing for a proposed stock sale. The article aims to help investors track CareDx's financial performance, governance, and material events.
CareDx (CDNA) grows 2025 revenue 14% and guides higher for 2026
CareDx, Inc. reported strong financial results for full-year 2025, with revenue increasing 14% to $380 million, and provided an optimistic outlook for 2026, projecting revenue between $420 million and $444 million. The company achieved non-GAAP net income of $32 million and adjusted EBITDA of $32 million in 2025, while also announcing the appointment of Keith Kennedy as the new CFO and COO. Share repurchases totaling $88 million were conducted in 2025, and the company ended the year with approximately $201 million in cash and equivalents.
BTIG Raises CareDx (CDNA) Price Target to $26.00, Maintains Buy Rating | CDNA Stock News
BTIG analyst Mark Massaro has increased the price target for CareDx (CDNA) from $25.00 to $26.00, maintaining a Buy rating. This adjustment reflects a 4% increase in the price target and continued confidence in the company's market performance. Other analysts, including Wells Fargo, have also recently raised their price targets for CareDx, indicating a positive sentiment across the board.
BTIG raises CareDx stock price target to $26 on strong Q4 results
BTIG has increased its price target for CareDx, Inc. (NASDAQ:CDNA) to $26 from $25, maintaining a Buy rating, following the diagnostics company's strong fourth-quarter results. CareDx reported a 25% revenue increase, achieved $380 million in revenue over the last twelve months, and provided 2026 revenue guidance above analyst estimates. Despite a delay in the final CMS LCD release, BTIG believes the stock is undervalued, noting its current trading multiples are well below historical averages and industry peers.
CareDx (NasdaqGM:CDNA) Stock Forecast & Analyst Predictions
CareDx (NasdaqGM:CDNA) is projected to achieve significant growth, with earnings and revenue expected to increase by 95.1% and 11.2% per annum, respectively. The company is forecast to become profitable within the next three years, outpacing the average market growth and savings rate. Analysts maintain a positive outlook, with several providing updated earnings guidance and clinical validation results for new products.
CareDx, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-02-24
CareDx, Inc. announced its Q4 2025 earnings, reporting an EPS of $0.12, which missed estimates by $0.11. However, the company's revenue reached $108.39 million, exceeding expectations by $5.64 million and representing a 25.19% year-over-year increase. This presentation was published in conjunction with their earnings call.
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
CareDx, Inc. reported strong financial results for the fourth quarter and full year ended December 31, 2025. The company achieved full-year 2025 total revenue of $380 million, representing a 14% year-over-year increase, and provided 2026 revenue guidance between $420 million and $444 million. These results reflect disciplined execution, continued momentum in core services, and strategic advancements in precision transplant diagnostics.
Jupiter Asset Management Ltd. Sells 128,669 Shares of CareDx, Inc. $CDNA
Jupiter Asset Management Ltd. significantly reduced its stake in CareDx, Inc. (NASDAQ:CDNA) by selling 128,669 shares, representing a 64.9% decrease, and now holds 69,715 shares valued at approximately $1.01 million. This comes as CareDx CEO John Walter Hanna Jr. also sold a substantial number of shares, and company insiders have collectively sold over $625,000 worth of stock in the last three months. Analyst ratings for CareDx are predominantly "Hold," with an average target price of $26.67.
(CDNA) Movement as an Input in Quant Signal Sets
The article analyzes Caredx Inc. (NASDAQ: CDNA) using AI models, highlighting a weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis emphasizes a significant risk-reward short setup for CDNA.
CareDx to join Raymond James 47th investor conference | CDNA Stock News
CareDx, Inc., a leading precision medicine company for transplant patients, announced its participation in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL, on March 3, 2026. This conference offers an opportunity for the company to engage with institutional investors. CareDx focuses on developing and commercializing high-value healthcare solutions for transplant patients and caregivers.
CareDx, Inc. (CDNA) Stock Analysis: 15.75% Potential Upside Beckons Investors
CareDx, Inc. (CDNA), a healthcare company specializing in diagnostic solutions for transplant patients, shows a potential upside of 15.75% based on analyst target prices. Trading at $19.87, the stock's forward P/E ratio suggests investor optimism, while robust financials and strategic partnerships underscore its growth potential. Despite mixed analyst ratings, a low RSI indicates a possible buying opportunity in the diagnostics and research sector.
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
CareDx, Inc., a precision medicine company specializing in transplant patient solutions, announced its participation in the Raymond James 47th Annual Institutional Investors Conference. The conference will be held in Orlando, FL, on Tuesday, March 3, 2026. CareDx focuses on improving outcomes for transplant patients through various services, including non-invasive molecular testing, digital health technologies, and patient solutions.
Zweig DiMenna Associates LLC Buys 348,400 Shares of CareDx, Inc. $CDNA
Zweig DiMenna Associates LLC significantly increased its stake in CareDx, Inc. ($CDNA) by purchasing an additional 348,400 shares, bringing its total holdings to 575,000 shares, valued at approximately $8.36 million. Despite this institutional buying, the article also notes insider selling by CEO John Walter Hanna Jr. and a consensus "Hold" rating from analysts with an average target price of $26.67. CareDx (NASDAQ:CDNA) is a precision diagnostics company specializing in tests for transplant patients.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx announced positive clinical validation data for AlloHeme, a new blood-based monitoring test designed to predict relapses in AML and MDS patients following allogeneic hematopoietic cell transplant. The ACROBAT study demonstrated AlloHeme's high diagnostic accuracy and ability to detect relapse earlier than traditional methods, supporting its commercialization beginning in 2027 as part of CareDx’s Transplant+ strategy. This advancement positions CareDx for growth in the cell therapy and hematologic oncology markets, expanding its precision medicine portfolio.
CareDx (CDNA) Projected to Post Earnings on Tuesday
CareDx (NASDAQ:CDNA) is expected to release its Q4 2025 earnings before the market opens on Tuesday, February 24th, with analysts projecting earnings of $0.24 per share and revenue of $102.76 million. The company's shares were up approximately 2.8%, trading at $19.63, and analysts have a consensus "Hold" rating with a target price of $26.67. Recent insider selling by CEO John W. Hanna Jr. and varying institutional investor activities have also been noted.
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CareDx recently announced positive clinical validation data for its AlloHeme blood test, designed to predict relapses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplant (HCT). The ACROBAT study demonstrated AlloHeme's high sensitivity and specificity, detecting relapses earlier than standard methods. This development strengthens CareDx's expansion into cell therapy and hematologic oncology, with commercialization planned for 2027.
